[1] Y. Yang et al. 4MO - Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study. Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856
[2] C. Zhou 3MO - First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trial. Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856
[3] D. Rodriguez Abreu et al. 6MO - Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC With PD-L1 tumor proportion score≥50%: KEYNOTE-598 3-year follow-up. Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856
[4] S. Wu et al. 12P - A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs. Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856
[5] K. Chen et al. 21P - Sintilimab in combination with anlotinib in non-small-cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study. Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856